Kaya, FatmaArslan, DeryaVatansev, HüsamettinKöse, DoğanÇimen, DeryaAkyürek, FikretOran, Bülent2020-03-262020-03-2620161077-41141536-3678https://dx.doi.org/10.1097/MPH.0000000000000491https://hdl.handle.net/20.500.12395/33650Objectives:The aim of this study was to evaluate the importance of growth-differentiation factor-15 (GDF-15) levels and tissue Doppler imaging (TDI) in the early detection of anthracycline-induced cardiomyopathy during the treatment of childhood cancers.Patients and Methods:Twenty patients (13 males and 7 females) newly diagnosed with childhood cancer whose treatment protocol included anthracycline were included in the study. Echocardiography, including M-mode, pulse Doppler, and TDI, was performed after the first anthracycline treatment at cumulative doses of 100, 200, and 300 mg/m(2) and at least 6 months after the last treatment. GDF-15 and troponin-I were also measured at these time points.Results:The median age of the patients was 14 years (range, 3 to 18 y). The median cumulative anthracycline dose was 220 mg/m(2) (range, 60 to 400 mg/m(2)). Conventional pulse wave and pulse wave tissue Doppler methods revealed significant differences in the right ventricular myocardial performance indices of the patients who received cumulative anthracycline doses of 300 mg/m(2) compared with their indices at least 6 months after the last treatment. The serum GDF-15 levels after the cumulative anthracycline dose of 200 mg/m(2) were also higher than the patients' pretreatment levels.Conclusions:Doppler/TDI and GDF-15 levels may be used in the early determination of anthracycline-induced cardiomyopathy during the treatment of childhood cancers.en10.1097/MPH.0000000000000491info:eu-repo/semantics/closedAccessanthracycline cardiotoxicitychildrengrowth-differentiation factor-15tissue Doppler imagingArticle383E107E11226907646Q3WOS:000374777900005Q4